Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 8/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29501072 | 0.76 | TERT (0.54) | CYP2A6CYP3A4ALDH1A1CYP1A2KDM4E | |
| SCHEMBL7247273 | 0.76 | CYP2A6 (0.47) | CYP2A6CYP3A4ALDH1A1CYP1A2KDM4E | |
| SCHEMBL185112 | 0.76 | TERT (0.54) | CYP2A6CYP3A4ALDH1A1CYP1A2KDM4E | |
| SCHEMBL2423305 | 0.75 | TERT (0.52) | CYP2A6CYP3A4ALDH1A1CYP1A2KDM4E | |
| SCHEMBL30385992 | 0.75 | TERT (0.52) | CYP2A6CYP3A4ALDH1A1CYP1A2KDM4E | |
| SCHEMBL29021355 | 0.75 | TERT (0.52) | CYP2A6CYP3A4ALDH1A1CYP1A2KDM4E | |
| SCHEMBL21808804 | 0.75 | TERT (0.52) | CYP2A6CYP3A4ALDH1A1CYP1A2KDM4E | |
| SCHEMBL11965538 | 0.72 | CYP2A6 (0.78) | CYP2A6CYP3A4ALDH1A1CYP1A2KDM4E | |
| SCHEMBL14445603 | 0.71 | TOP1 (0.62) | CYP2A6CYP3A4ALDH1A1CYP1A2CYP19A1 | |
| SCHEMBL7240682 | 0.68 | TERT (0.46) | KDM4ECYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7001588-B2 | Expanded porphyrin compositions for tumor inhibition | CYLENE PHARMACEUTICALS (US) | 2006-02-21 | — | — | US | disclosed |
| US-20040110820-A1 | Expanded porphyrin compositions for tumor inhibition | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110820-A1 | Expanded porphyrin compositions for tumor inhibition | MYC, MYCBP, TP53 | CYP2A6 3784/4885CYP3A4 3225/4885ALDH1A1 4454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.